Shape Therapeutics
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Gene therapy, RNA therapeutics, AAV delivery, Life sciences
- Founded
- 2018 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Shape Therapeutics Inc Seattle business license
Recent coverage
Front-page news, podcasts and videos about Shape Therapeutics
Flexe hires Amazon biometrics lead Lara Rogers as SVP/GM; Magnify names ex‑Amazon Sajo Jacob CTO; Schuster joins Open Systems board
Several Seattle-area tech companies announced senior hires and board moves: Flexe hired former Amazon biometrics leader Lara Rogers as SVP and GM; Magnify named Sajo Jacob as CTO and co‑founder after a $6M launch; Open Systems added ex‑Microsoft exec Gavriella Schuster to its board; Fabric and Scener also announced senior appointments.
CBRE: U.S. life-sciences VC tops $30B; Seattle-area firms raise $898M amid scarce lab space
A CBRE report shows U.S. life sciences venture funding topped $30 billion for the 12 months ending September 2021, driving strong demand for lab space and record capital raises in Seattle-area companies that pulled in $898 million during that period. Washington state also saw rising life-science employment and multiple biotech IPOs in 2021, including large offerings from Sana Biotechnology, Absci and Icosavax.
Shape Therapeutics raises $112M to advance RNA-editing platform and AAV gene-delivery for neurological and genetic diseases
Seattle preclinical biotech Shape Therapeutics raised $112 million to develop RNA-editing and gene therapy technologies, including improved AAV delivery vectors and an RNA editing platform. The company, led by CEO and co-founder Francois Vigneault and leveraging work from co-founder Prashant Mali, aims to target neurological and genetic diseases such as Parkinson's, Alzheimer’s, alpha-1 antitrypsin deficiency, and Rett syndrome.
By Shape Therapeutics
Shape Therapeutics and Rett Syndrome Research Trust partner to advance SHP-401 AI-designed RNAfix® therapy correcting MECP2 R168X toward IND studies
Shape Therapeutics and the Rett Syndrome Research Trust partnered to fund translational studies of SHP-401, an intravenously delivered, one-time RNAfix® gene therapy using AI-designed guide RNA to correct the MECP2 R168X mutation for Rett syndrome. Preclinical mouse data posted to bioRxiv show ~70% RNA editing in the brain and restoration of full-length MeCP2 after a single IV dose, supporting IND-enabling study goals in non-human primates.
